Filing Flows › Biolargo (BLGO) › Q1 2026 › vs Q4 2025
Biolargo (BLGO) Q1 2026 vs Q4 2025 (quarter over quarter)
Biolargo's revenue rose $498K (+81%) from $617K in Q4 2025 to $1.1M in Q1 2026. The biggest changes: Product +$394K (+215%); Service +$104K (+24%).
Biolargo, Q1 2026: revenue $1.1M (-66% year over year), operating margin -287.4%, net loss $3.4M, operating cash flow −$2.9M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Product | $577K | $183K | $394K | +215% |
| Service | $538K | $434K | $104K | +24% |
| Revenue | $1.1M | $617K | $498K | +81% |
| Net loss | $3.4M | $4.1M | −$737K | -18% |
| Costs & expenses | $4.5M | $4.8M | −$239K | -5% |
| Operating costs | $4.3M | $4.6M | −$309K | -7% |
| Interest & other, net | $201K | $131K | $70K | +53% |
| Cost of revenue | $657K | $489K | $168K | +34% |
| Research & development | $907K | $659K | $248K | +38% |
| SG&A | $2.8M | $3.4M | −$674K | -20% |
| Operating cash sources | $3.6M | $2.6M | $1.0M | +38% |
| Depreciation | $34K | $33K | $1K | +3% |
| Share-based compensation | $699K | $1.0M | −$315K | -31% |
| Cash used in operations | $2.9M | $1.6M | $1.3M | +83% |
| Net loss absorbed | $3.4M | $4.1M | −$737K | -18% |
| Working capital & other | $245K | −$1.5M | $1.8M | — |
Questions
How much did Biolargo's revenue grow quarter over quarter in Q1 2026?
Biolargo's revenue rose $498K (+81%) from $617K in Q4 2025 to $1.1M in Q1 2026.
What drove Biolargo's revenue change in Q1 2026?
Product +$394K (+215%); Service +$104K (+24%).